Yale University

Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.

TitlePatient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir.
Publication TypeJournal Article
Year of Publication2012
AuthorsEdelman, Jennifer E., Kirsha Gordon, Maria C. Rodriguez-Barradas, and Amy C. Justice
Corporate AuthorsVACS Project Team
JournalAIDS patient care and STDs
Date Published2012 Jun
KeywordsAdenine, Anti-HIV Agents, Benzoxazines, Cohort Studies, Cross-Sectional Studies, Deoxycytidine, Drug Therapy, Combination, Female, Health Status, HIV Infections, Humans, Male, Middle Aged, Organophosphonates, Quality of Life, Severity of Illness Index, Treatment Outcome, Veterans
AbstractMost patients (80-90%) newly diagnosed with HIV are started on the antiretroviral regimen efavirenz, emtricitabine, and tenofovir (EFV/FTC/TDF). Existing studies of patient tolerability, however, are limited. We compared symptom experiences of patients on EFV/FTC/TDF, and the subsequent impact on health-related quality of life, with those of patients on other combination antiretroviral therapy (cART). We conducted a cross-sectional analysis of the Veterans Aging Cohort Study from February 2008 to August 2009 to compare the symptom experiences of patients on EFV/FTC/TDF vs. other cART, unadjusted and then adjusted for treatment characteristics, and comorbid disease severity. We then assessed the association between EFV/FTC/TDF use and health-related quality of life. Among the 1,759 patients in our analytic sample, EFV/FTC/TDF use was associated with fewer symptoms than was other cART. The use of EFV/FTC/TDF was independently associated with health-related quality of life, and this association was at least partially explained by symptom burden.
Alternate JournalAIDS Patient Care STDS

External Links